1812 Ashland Avenue, 1st Floor
About WindMIL Therapeutics
When it comes to cell therapy – cell source matters. At WindMIL, we are harnessing the power of bone marrow derived lymphocytes (MILs) to develop ground-breaking immunotherapies to treat cancer patients. The bone marrow is a natural reservoir of T cells with unique advantages including inherent tumor-specificity. We have perfected an efficient and rapid process to extract, activate and expand MILs for future commercial applications. Our lead program is in a large Phase 2b study in high-risk multiple myeloma with additional programs in solid tumors using MILs advancing to the clinic. We are also advancing programs to supercharge MILs through genetic-modification.
Founders: Ivan Borrello, MD and Kimberly Noonan, PhD
CEO: Brian Halak, PhD
CMO: Dr. Steven Fischkoff
CSO: Kimberly Noonan, PhD
Please click here for WindMIL's technology.
3 articles with WindMIL Therapeutics
Phase 2, multi-center randomized trial of MILs™ in high-risk multiple myeloma fully enrolled
WindMIL Therapeutics, based in Baltimore, Maryland, filed a form D with the U.S. Securities and Exchange Commission, indicating it had raised $32.53 million in equity financing.
WindMIL Therapeutics Announces New Cancer Immunotherapy Approach Based On Marrow-Infiltrating Lymphocytes